Deljean Buenaventura
Family · Phoenix, AZNPI 1174993612
Payments from drug & device makers
Across 168 payments — averaging $40.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$847
- United Therapeutics Corporation$668
- Boehringer Ingelheim$653
- Astellas Pharma US Inc$586
- AstraZeneca$417
- Grifols USA, LLC$397
- plus $3K from 32 others
What the payments were for
- Consulting fees$2003%
- Food & beverage$5,47181%
- Education$1,07016%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 19 | $847 |
| United Therapeutics Corporation | 16 | $668 |
| Boehringer Ingelheim | 19 | $653 |
| Astellas Pharma US Inc | 15 | $586 |
| AstraZeneca | 12 | $417 |
| Grifols USA, LLC | 8 | $397 |
| Novo Nordisk | 3 | $318 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $286 |
| Bayer | 3 | $235 |
| Regeneron Healthcare Solutions, Inc. | 3 | $200 |
| Amgen | 4 | $176 |
| Verona Pharma, Inc. | 3 | $169 |
| Sanofi | 8 | $163 |
| Aimmune Therapeutics, Inc. | 2 | $157 |
| Gilead | 1 | $125 |
| Inspire Medical Systems, Inc. | 1 | $118 |
| Merck | 4 | $109 |
| Pharming Healthcare, Inc. | 1 | $107 |
| Insmed, Inc. | 5 | $106 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Abbott | 1 | $91 |
| Vifor Pharma, Inc. | 3 | $89 |
| Pulmonx Corporation | 1 | $84 |
| Philips North America LLC | 4 | $74 |
| Baxter Healthcare | 4 | $66 |
| Chiesi USA, Inc. | 2 | $55 |
| Mylan Specialty L.p. | 2 | $55 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| Electromed, Inc. | 3 | $38 |
| Biomerieux Inc | 1 | $33 |
| Covis Pharma GmbH | 1 | $30 |
| AbbVie | 1 | $27 |
| Viatris Specialty LLC | 1 | $24 |
| Invivyd Inc | 1 | $22 |
| Shionogi Inc | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Grifols Shared Services North America, Inc. | 1 | $17 |
| Genentech, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,741 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 191 | $2,340,265 |
| Tyvaso DpiTreprostinil | 20 | $502,037 |
| Pirfenidone | 52 | $193,982 |
| CaystonAztreonam Lysine | 13 | $153,872 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $93,825 |
| Dupixent PenDupilumab | 12 | $42,716 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $25,957 |
| Spiriva HandihalerTiotropium Bromide | 19 | $18,658 |
| Spiriva RespimatTiotropium Bromide | 24 | $16,969 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $12,919 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $10,488 |
| Mycophenolate Mofetil | 53 | $8,325 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $7,273 |
| Everolimus | 13 | $4,947 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $4,606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $653 | $2,357,234215 claims |
| GileadCayston | $125 | $153,87213 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $417 | $38,87673 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Phoenix
- Kimberly HallaPhoenix$332K
- Audrey StevensonPhoenix$83K
- Rebekah EdwardsPhoenix$51K
- Tirsa QuartulloPhoenix$31K
- Jessica AcostaPhoenix$30K
- Stephanie JohnstonPhoenix$25K
- Kelly MarcelloPhoenix$23K
- Judith BergmanPhoenix$22K
- Lauren BonnerPhoenix$22K
- Rita GonzalezPhoenix$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.